Everyday Health on MSN
Novel targeted therapies for IgAN: What you need to know
Explore novel therapies for IgA nephropathy that target inflammation and antibody production. Learn how these advancements ...
Today, the American Kidney Fund (AKF) and the IgA Nephrology Foundation announce the creation of a new resource for IgA nephropathy patients and their loved ones: the IgA nephropathy patient ...
Verywell Health on MSN
7 types of treatments for IgA nephropathy
Medically reviewed by Jamin Brahmbhatt, MD IgA nephropathy (IgAN) is a kidney condition where antibodies (immune system ...
Vera Therapeutics (NASDAQ:VERA) said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease ...
IgA nephropathy, also known as Berger’s disease, is a progressive, autoimmune, chronic kidney disease that predominantly affects adults between the ages of 20 and 40. It is characterized by the ...
The FDA has granted full approval to iptacopan (Fabhalta) to slow the decline in kidney function in adults with primary ...
Dr Suneel Udani vividly recalls, as a first-year fellow, caring for a patient with IgA nephropathy whose condition deteriorated despite their best efforts, due to the limited treatment options ...
Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing immune complexes (IgA-ICs) in the glomerular mesangium, leading to mesangial ...
Learn why Oxford scores predict IgA nephropathy outcomes, and how supportive drugs plus low-salt lifestyle protect remaining nephrons. How does targeted-release budesonide different from systemic ...
After an IgA nephropathy (IgAN) diagnosis, your care team has likely discussed different treatment options with you, including some newer targeted therapies such as targeted-release budesonide or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results